Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
Date:2/15/2008

HONG KONG, Feb. 15 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132).

The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a Genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5% at six months is highly acceptable when compared to published primary percutaneous coronary intervention (PCI) rates for bare metal stents. The paper also highlighted the low rate of major adverse cardiac events (MACE): 4.2% at 30 days and 5.8% at six months.

Entitled "Use of endothelial progenitor cell capture stent (Genous Bio-engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow up," the paper was authored by Dr. Huay Cheem Tan. The study was conducted at National University Hospital and Tan Tock Seng Hospital in Singapore.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Global Media Contact:

David Schull

Russo Partners LLC

+1 212-845-4271 (office)

+1 858-717-2310 (mobile)

david.schull@russopartnersllc.com


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
6. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
7. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
8. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
9. Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
10. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
11. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of ... a high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered ... ducted hoods in the laboratory. , Attendees will learn from an industry expert ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... DFS) cybersecurity regulations have transitioned into full force and effect. The law ... state (“Covered Entities”) to conduct an annual, professional, comprehensive cybersecurity risk assessment, ...
(Date:9/18/2017)... --  Montrium , a growing leader in Electronic Trial Master ... groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic Studies (MAPS). ... MAPS Public Benefit ... ... to MDMA for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS ...
Breaking Biology Technology:
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
Breaking Biology News(10 mins):